| Name | Title | Contact Details |
|---|
Transgene SA is a France-based fully integrated biopharmaceutical company specialising in immunotherapeutics to treat cancer and infectious diseases. The company has subsidiaries in China and in the USA.
A world leader in the field of in vitro diagnostics for more than 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2015, revenues reached €1.965 billion with 90% of sales outside of France. bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Marina Biotech`s focus is to treat the intersection of arthritis, pain, hypertension, and oncology diseases using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics. The company`s `next-generation of celecoxib,` including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combating the opioid epidemic. They are also being developed as anticancer agents against FAP and CRC. On the Sales and Marketing front- we are actively promoting sales and distribution of our FDA approved drug- Prestalia- through our patient centric care program: 1) We have developed a patented total care program which increase compliance to over 80%. 2) Increase compliance is expected to improve care for hypertensive patients, especially resistant hypertensive patients which currently have no treatment available to them. 3) Resistant hypertension market size is large with 22% of all hypertensive pts eventually become resistant hypertension 4) Compliance/counseling has been shown clinically to treated resistant hypertensive patients 5) Deep pipeline a. Perindopril- Hypertension monotherapy. ACEON (Perindopril) NDA b. Prestalia- Hypertension combination therapy. i. Perindopril/Amlodipine, ii. 1st line hypertension, c. Atorvastatin/Perindopril: Hypertension and lipid disorder d. Pipeline drug: Hypertension and Pain. IT-102, IT-103
KPL is committed to protecting the privacy of our customers. Our Privacy Policy covers any personal information that KPL.com obtains from you when you use services on our site. We use this information to enhance our services and to make them more
Clario is a leading healthcare research and technology company that generates the richest clinical evidence in the industry for our pharmaceutical, biotech and medical device partners. Across decentralized, hybrid and site-based trials, our deep scientific expertise, global scale and the broadest endpoint technology platform in the industry allows our partners to transform lives. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion, and respiratory endpoints. Clario`s global team of science, technology and operational experts have helped deliver more than 27,000 trials and contributed to over 500 FDA and EMEA new drug approvals involving more than seven million participants in over 100 countries. Our innovation has been transforming clinical trials for 50 years.